MedTrace Logo

STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism

NCT07603700 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2026-05-22

No results posted yet for this study

Summary

This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.

Conditions

Interventions

DRUG

Anticoagulants

Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.

DRUG

Thrombolytic Agents

Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.

DEVICE

Mechanical Thrombectomy Devices

Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-03-01
Completion
2029-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07603700 on ClinicalTrials.gov